INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing precision brain-computer interfaces (BCIs) powered by graphene, today announced it has been selected as a 2025 Technology Pioneer by the World Economic Forum.

by the Spanish Ministry of Industry and Tourism through the PERTE Chip initiative. The grant will accelerate INBRAIN’s development of BCI technology that integrates intelligent computing and graphene-based materials to decode and modulate real time brain activity for therapeutic purposes.

About INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is advancing real-time precision neurology with the world’s first graphene-based brain-computer interface therapeutics (BCI-Tx) platform. Using high-resolution neural decoding and targeted micromodulation, INBRAIN delivers personalized, adaptive treatments for neurological conditions like Parkinson’s disease, epilepsy, and stroke rehabilitation. The company is developing autonomous BCI therapeutics that continuously monitor and adjust therapy in real time to enhance outcomes and minimize side effects, and has earned FDA Breakthrough Device Designation for its application in Parkinson’s disease. In partnership with Merck KGaA and through its subsidiary INNERVIA Bioelectronics, INBRAIN is also developing bioelectronic therapies for peripheral and systemic diseases. Learn more at www.inbrain-neuroelectronics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623776115/en/